menu
    • menu
    [{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Selexipag","moa":"Prostanoid IP receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Actelion Pharmaceuticals Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Beyond Batten Disease Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Miglustat","moa":"GCS","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Beyond Batten Disease Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Actelion Pharmaceuticals Ltd \/ Beyond Batten Disease Foundation"},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Ponesimod","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Actelion Pharmaceuticals Ltd","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Tablet, Film Coated","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Actelion Pharmaceuticals Ltd \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Actelion Pharmaceuticals Ltd","sponsor":"Juvise Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Ponesimod","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Actelion Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Actelion Pharmaceuticals Ltd \/ Juvise Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Actelion Pharmaceuticals Ltd \/ Juvise Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Actelion Pharmaceuticals Ltd

    Menu

    Actelion Pharmaceuticals Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ponesimod

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Juvise Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Juvisé Pharmaceuticals Acquires Ponvory® Ex-US/Canada and Opens Capital To Bpifrance

                            Details : Juvise Pharmaceuticals will leverage its expertise to commercialize Ponvory (ponesimod), a first-line treatment option for active forms of relapsing multiple sclerosis outside of North America.

                            Brand Name : Ponvory

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : Ponesimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Juvise Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ponesimod

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Vanda Pharmaceuticals

                            Deal Size : $100.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator ...

                            Details : Through the acquisition, Vanda expands its commercial portfolio by including Ponvory (ponesimod), a daily oral selective sphingosine-1-phosphate receptor 1 (S1P1R) modulator, indicated to treat adults with relapsing forms of multiple sclerosis.

                            Brand Name : Ponvory

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 07, 2023

                            Lead Product(s) : Ponesimod

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Vanda Pharmaceuticals

                            Deal Size : $100.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Miglustat,Trehalose API

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Beyond Batten Disease Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Beyond Batten Disease Foundation Announces Agreement with Actelion Pharmaceuticals Ltd to Provide Drug Product...

                            Details : Janssen will provide drug supply for the clinical trials and Extended Access Program, and right of reference to data within the Zavesca New Drug Application (NDA) to support the development of BBDF-101.

                            Brand Name : BBDF 101

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 02, 2021

                            Lead Product(s) : Miglustat,Trehalose API

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Beyond Batten Disease Foundation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Actelion Pharmaceuticals Ltd

                            Switzerland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Selexipag,Macitentan,Tadalafil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress

                            Details : While the primary endpoint was not met, exploratory analysis suggests a signal of reduced risk of disease progression of initial triple oral combination therapy vs initial double oral therapy for Pulmonary Arterial Hypertension (PAH) patients .

                            Brand Name : Uptravi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 29, 2020

                            Lead Product(s) : Selexipag,Macitentan,Tadalafil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth